These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35900488)

  • 21. Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness.
    Karasavvidou F; Barbanis S; Pappa D; Moutzouris G; Tzortzis V; Melekos MD; Koukoulis G
    Arch Pathol Lab Med; 2008 Dec; 132(12):1912-5. PubMed ID: 19061289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
    Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Micropapillary urothelial carcinoma of urinary bladder displays immunophenotypic features of luminal and p53-like subtypes and is not a variant of adenocarcinoma.
    Yang Y; Kaimakliotis HZ; Williamson SR; Koch MO; Huang K; Barboza MP; Zhang S; Wang M; Idrees MT; Grignon DJ; Eble JN; Baldridge LA; Cheng L
    Urol Oncol; 2020 May; 38(5):449-458. PubMed ID: 31740332
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular stratification of high-grade urothelial carcinoma by immunohistochemistry with its histomorphological and clinical correlation.
    Gupta G; Gupta R; Pasricha S; Sharma A; Durga G; Kamboj M; Tripathi R; Mehta A
    Indian J Pathol Microbiol; 2022; 65(4):832-838. PubMed ID: 36308189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
    Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
    Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers.
    Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M
    BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP; Tsoli E; Fouskakis D; Yiotis J; Koullias GJ; Giannopoulos D; Papalambros E; Nikiteas NI; Spiliopoulou CA; Patsouris E; Asimacopoulos P; Gorgoulis VG
    Anticancer Res; 2004; 24(3b):2061-8. PubMed ID: 15274401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human epidermal growth factor receptor 2 neu expression in head and neck squamous cell cancers and its clinicopathological correlation: Results from an Indian cancer center.
    Vats S; Ganesh MS; Agarwal A
    Indian J Pathol Microbiol; 2018; 61(3):313-318. PubMed ID: 30004046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder.
    Calvete J; Larrinaga G; Errarte P; Martín AM; Dotor A; Esquinas C; Nunes-Xavier CE; Pulido R; López JI; Angulo JC
    Hum Pathol; 2019 Sep; 91():61-68. PubMed ID: 31279874
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Micropapillary urothelial carcinoma: evaluation of HER2 status and immunohistochemical characterization of the molecular subtype.
    Zinnall U; Weyerer V; Compérat E; Camparo P; Gaisa NT; Knuechel-Clarke R; Perren A; Lugli A; Toma M; Baretton G; Kristiansen G; Wirtz RM; Cheng L; Wullich B; Stoehr R; Hartmann A; Bertz S
    Hum Pathol; 2018 Oct; 80():55-64. PubMed ID: 29885409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
    Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
    Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.
    Choi W; Czerniak B; Ochoa A; Su X; Siefker-Radtke A; Dinney C; McConkey DJ
    Nat Rev Urol; 2014 Jul; 11(7):400-10. PubMed ID: 24960601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
    Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
    Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications.
    Chen C; Yuan JP; Wei W; Tu Y; Yao F; Yang XQ; Sun JZ; Sun SR; Li Y
    Int J Nanomedicine; 2014; 9():1039-48. PubMed ID: 24591826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cell blocks allow reliable evaluation of expression of basal (CK5/6) and luminal (CK8/18) cytokeratins and smooth muscle actin (SMA) in breast carcinoma.
    Delgallo WD; Rodrigues JR; Bueno SP; Viero RM; Soares CT
    Cytopathology; 2010 Aug; 21(4):259-66. PubMed ID: 19843143
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer].
    Coronado Martín PJ; Fasero Laiz M; García Santos J; Ramírez Mena M; Vidart Aragón JA
    Med Clin (Barc); 2007 Jan; 128(1):1-6. PubMed ID: 17266884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.
    Kikuchi S; Nishimura R; Osako T; Okumura Y; Nishiyama Y; Toyozumi Y; Arima N
    Anticancer Res; 2013 Sep; 33(9):3891-7. PubMed ID: 24023325
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunohistochemical characterisation of breast cancer: towards a new clasification?].
    Piñero-Madrona A; Polo-García L; Alonso-Romero JL; Salinas-Ramos J; Canteras-Jordana M; Sola-Pérez J; Galindo-Fernández PJ; Illana-Moreno J; Bermejo-López J; Navarrete-Montoya A; Parrilla-Paricio P
    Cir Esp; 2008 Sep; 84(3):138-45. PubMed ID: 18783672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.